التفاصيل البيبلوغرافية
| العنوان: |
ARGX-110 AND ARGX-111 RECEIVE ACCELERATED GRANT. |
| المصدر: |
Biotech Financial Reports. Oct2014, Vol. 21 Issue 10, p5-7. 3p. |
| مصطلحات موضوعية: |
*DRUG patents, PATENT expiration, PATENT extensions, THERAPEUTIC use of immunoglobulins, CD antigens |
| الشركة/الكيان: |
ARGENX NV |
| مستخلص: |
The article reports on the patents received by biopharmaceutical company arGEN-X NV for its two SIMPLE Antibody products such as ARGX-110 and ARGX-111. It says that the patent rights is expected to expire in 2031-2032, but are eligible for extension by up to five years of Patent Term Extension for marketing delays. Other topics discussed include the patent for arGEN-X's SIMPLE Antibody platform technology, the ARGX-110, which targets CD70 antigens, and ARGX-111 that targets c-Met receptor. |
| قاعدة البيانات: |
Business Source Index |
